Abstract: Traditional prediction models are focused on obtaining probabilities of relapse-free or overall survival based on clinical factors known at diagnosis or at the start of primary treatment. They are used to inform treatment decisions, to provide personalized risk estimates for the patient, and to stratify patients in clinical trials. There is little doubt that available prediction models are important tools for the treating physician to guide treatment decisions at diagnosis or, in the case of SCT, at transplant. However, once primary treatment has been initiated, the prognosis of the patient will change over the course of time, because of clinical events such as graft-versus-host disease or relapse that may have occurred, additional treatments given after primary treatment, and, very simply, because of the fact that the patient is still alive. The concept of updating the prognosis of the patient, taking into account information that has become available during followup, is called dynamic prediction. The objective of this talk is to illustrate and contrast two leading methods for dynamic prediction, multi-state models and landmarking, a method traditionally used to estimate the effect of time-dependent covariates. Data from the EBMT CLL Data Quality Initiative will be used as an example, with overall survival as endpoint and relapse as intermediate event. All outcomes will be adjusted for age at SCT, remission status, donor type and gender match. The results of these analyses allow to describe the impact of covariates at certain landmarks or in relation to intermediate events, e.g. age at SCT and relapse were clear risk factors for death, also for patients who had survived a number of years after SCT. HLA-identical siblings showed better survival, but this advantage was lost after relapse. Dynamic prediction probabilities were similar for the multistate model and the landmarking approach. The preferred method of choice depends on the wish to obtain comprehensive models, and on issues of robustness and ease of computation. Disclosure of Interest: None declared. Introduction: The assessment of long-term outcomes in transplanted patients helps to investigate the curative potential of alloSCT. Specialized statistical methods are needed for this, especially if an older population with non-negligible background mortality is studied. Similar methods can be used for non-fatal events, such as the incidence of malignancies for patients suffering from a non-malignant disease.
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Patients and methods: Standard Cox models are less suitable for long-term outcomes because of the differential impact of risk factors on disease-specific and background mortality and because of possible time-dependent effects of the risk factors. The main alternatives are cure models, landmark models and relative survival models. We studied survival of a cohort of CLL patients transplanted between 2000 and 2010 and registered with the EBMT, focusing on excess mortality with respect to the general population for patients who survived 2 and 5 years progression-free. Such a population could be considered 'cured' in the statistical sense of the word if excess mortality decreased to 0. Median age was 55 years at alloSCT. Excess mortality was assessed by means of an additive Cox model for relative survival, in which the CLL population was compared to a synthetic cohort of the general population. Each patient was matched to an artificial control with the same gender, country and age in the year of SCT. These Cox models contained sex, age and year of SCT. In another study, we studied excess risk of malignancies after treatment by immunosuppressive therapy in a cohort of patients with acquired aplastic anemia (aAA) treated at the Leiden University Medical Center. This competing risks outcome was also compared to malignancy incidence in the general Dutch population by means of the Standardized Incidence Ratio (SIR), taking into account the age and sex distribution of the aAA cohort and the competing events alloSCT and death. Results: In the CLL cohort, excess mortality was highest briefly after SCT, but continued to be above 0 in the landmark populations, even at 10 years after SCT. The adverse impact of higher age increased between the 2-year and 5-year landmark. Although in the general population females have a higher life expectation than males, there was no difference in excess mortality. In the aAA cohort, a significantly increased SIR of 3.35 indicated the long-term increased risk of malignancies not due to alloSCT. Discussion: Relative survival methods help to separate longterm treatment outcomes between those expected in the comparable general population and the excess burden due to the disease and treatment. In the absence of detailed molecular data and in populations where significant background mortality plays a role, these models give a clue about cure probability. Disclosure of Interest: None declared.
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Survival probabilities when treatment is given during the follow-up: the Simon and Makuch method compared to multi-state and other approaches S. Iacobelli 1,* 1 Centro di Biostatistica e Bioinformatica, Università di Roma "Tor Vergata", Rome, Italy Abstract: The survival experience of two groups defined at baseline i.e. at the start of the follow-up is commonly summarized by survival curves obtained from the KaplanMeier (KM) non-parametric estimator. This approach however is not appropriate when the group allocation is dynamic in time allowing patients to switch from one group to another one, for example when the switch is the administration of a treatment. A typical problem is comparing single versus double autologous transplantation in myeloma patients in absence of a pre-specified (possibly randomized) intention-to-treat. A simple comparison of patients according to the treatment received -one against two transplantations -is biased as patients must survive for a sufficient period to receive the second transplantation, thus the "double auto given" group has by construction a survival advantage over the "single auto" group. One the most popular approaches to non-parametric estimation of survival probabilities in this situation is the Simon and Makuch or "extended Kaplan-Meier'' method (1984) . Following the rationale of the Mantel-Byar test (1974) the estimates of the survival probabilities are derived from pointwise hazards estimators where the risk sets are updated dynamically in time, with patients "disappearing" from the "single auto" group (artificial censoring) and "appearing" in the "double auto" group (left truncation) at the time of the switch. However as clarified by recent work by Bernasconi et al. (2014, submitted) this approach implicitly assumes that the risk of failure after the treatment switch (second transplantation in our example) does not depend on the time between the start (1st SCT) and the switch (2nd SCT) nor from the time elapsed since the switch (Markovian hypothesis). This assumption is not satisfied in many typical problems, for example when the switch is the administration of allogeneic transplantation there is a clear relevance of time since allo transplant is given, with higher mortality in the first months. Additionally, the interpretation of the Simon and Makuch (SM) curves as survival probabilities holds only in a counterfactual situation where the treatment was actually allocated at start. The talk will illustrate the SM approach and its limitations, comparing it to other common approaches like the use of landmark curves, and of multi-state models for dynamic prediction. The focus will be on the logic and the interpretation, with little emphasis on the mathematical background. Disclosure of Interest: None declared.
